Drug Search Results
More Filters [+]

Methylergometrine

Alternative Names: methylergometrine, methergine
Latest Update: 2024-05-01
Latest Update Note: Clinical Trial Update

Product Description

Methylergometrine is a semisynthetic ergot alkaloid and a derivative of ergonovine and is used for the prevention and control of postpartum and post-abortion hemorrhage. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Methylergonovine#section=Pharmacology-and-Biochemistry)

Mechanisms of Action: Apoptosis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intramuscular,Intravenous,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Algeria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | Czech | Denmark | Dominican Republic | Ecuador | Egypt | France | Greece | Iceland | India | Indonesia | Ireland | Italy | Jordan | Korea | Luxembourg | Malaysia | Malta | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Saudi Arabia | Serbia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United States | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Methylergometrine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title